Second Vioxx trial delay rejected by New Jersey judge

[JURIST] A New Jersey judge Monday rejected a motion by drugmaker Merck [corporate website] to postpone its scheduled second trial in connection with its Vioxx [JURIST report] painkiller, pulled off the market last year after it was found to increase the risk of heart attacks and strokes [FDA public health advisory] in some users. Superior Court Judge Carol Higbee said that a $253 million verdict [JURIST report] handed down by a Texas jury earlier this month did not preclude a fair trial for Merck in Atlantic City New Jersey, and turned down a bid to have the trial date put off for 45 days. Merck is facing almost 5000 Vioxx lawsuits in the United States, and has set aside a defense fund of over $675 million. Bloomberg has more.

 

About Paper Chase

Paper Chase is JURIST's real-time legal news service, powered by a team of 30 law student reporters and editors led by law professor Bernard Hibbitts at the University of Pittsburgh School of Law. As an educational service, Paper Chase is dedicated to presenting important legal news and materials rapidly, objectively and intelligibly in an accessible format.

© Copyright JURIST Legal News and Research Services, Inc., 2013.